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Abstract
Background: Despite enormous efforts to combat malaria the disease still afflicts up to half a billion people each
year of which more than one million die. Currently no approved vaccine is available and resistances to
antimalarials are widely spread. Hence, new antimalarial drugs are urgently needed.
Results: Here, we present a computational analysis of the metabolism of Plasmodium falciparum, the deadliest
malaria pathogen. We assembled a compartmentalized metabolic model and predicted life cycle stage specific
metabolism with the help of a flux balance approach that integrates gene expression data. Predicted metabolite
exchanges between parasite and host were found to be in good accordance with experimental findings when the
parasite’s metabolic network was embedded into that of its host (erythrocyte). Knock-out simulations identified 307
indispensable metabolic reactions within the parasite. 35 out of 57 experimentally demonstrated essential enzymes
were recovered and another 16 enzymes, if additionally the assumption was made that nutrient uptake from the
host cell is limited and all reactions catalyzed by the inhibited enzyme are blocked. This predicted set of putative
drug targets, shown to be enriched with true targets by a factor of at least 2.75, was further analyzed with respect
to homology to human enzymes, functional similarity to therapeutic targets in other organisms and their predicted
potency for prophylaxis and disease treatment.
Conclusions: The results suggest that the set of essential enzymes predicted by our flux balance approach
represents a promising starting point for further drug development.
Background
Malaria represents one of the major health issues world-
wide. According to WHO estimations there were
around 250 million clinical cases and about 1 million
disease related deaths in 2006 [1]. About 50% of the
world population lives in endemic areas, situated mostly
in Africa, Asia, and South-America [1].
Especially in Africa, where about 90% of the malaria
cases occur [1], the disease has significant negative
impact on the economic development [2]. Spreading
resistances have been developed over time to all but one
of the five major classes of antimalarial drugs [3]. As up
to now no approved vaccine is available, new effective
and affordable drugs are urgently needed.
Malaria is caused by protozoan parasites of the genus
Plasmodium, of which Plasmodium falciparum is
responsible for 90% of disease related deaths [1]. The
life cycle of this unicellular eukaryote is quite complex,
since it involves different hosts and tissues [4]. Parasites
injected via a mosquito bite into the human blood
stream first replicate within the liver and subsequently
periodically within erythrocytes. Mosquitos taking a
blood meal on infected individuals ingest parasites into
the midgut, where the only phase of sexual replication
takes place. Subsequently, the parasites migrate to the
mosquito’s salivary gland, in order to be reinjected into
the human host. Multiple genome-scale gene expression
analyses have been conducted in the last years that
allow for an insight into the changes of the transcrip-
tome of P. falciparum o v e rt h ec o u r s eo fi t sd e v e l o p -
ment. We evaluated in vitro and in vivo expression data
from five studies [5-9] that cover multiple time points * Correspondence: carola.huthmacher@charite.de
Institute of Biochemistry, Charité, Monbijoustraße 2, 10117 Berlin, Germany
Huthmacher et al. BMC Systems Biology 2010, 4:120
http://www.biomedcentral.com/1752-0509/4/120
© 2010 Huthmacher et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.during liver, blood, and mosquito stage of the parasite.
These data sets provide a starting point for further ana-
lyses of metabolic peculiarities during different time
points of parasite development.
Flux balance analysis (FBA) [10] is a computational
method to gain insight into the metabolic behavior and
capabilities of a cell. In contrast to kinetic modeling, no
detailed rate equations are required, predestining the
method for large metabolic networks which typically
lack full kinetic characterization of all enzymes. FBA
only necessitates knowledge about the stoichiometry of
a metabolic network as well as the metabolic target
functions underlying the cell of interest (e.g., biomass
production). Prediction quality improves if in addition
the present metabolic environment is known. Based on
this information the outcome of perturbations imposed
on a cellular system (e.g., variation in available nutrients
or the inhibition of certain enzymes) can be predicted as
has been shown for a variety of organisms [11-22]. FBA
facilitates the prediction of reactions essential for the
production of important metabolites, thus narrows
down the drug target search space and ultimately lowers
the cost for the whole drug design process. To our
knowledge, network based analyses of the metabolism of
P. falciparum have so far only been applied by Yeh et
al. [23] and Fatumo et al. [24]. Both authors performed
in silico knock-out studies to uncover putative drug tar-
gets in the parasite’s metabolism. However, both publi-
cations studied metabolic networks derived from the
BioCyc database that were not processed further using
additional information such as cellular compartments
and transport processes and therefore are of limited use-
fulness. Moreover, they did not consider the different
life cycle stages of the parasite, during which the meta-
bolism might vary due to varying availability of nutrients
in the different cellular environments.
The goal of this study was to explore stage-specific
metabolism of P. falciparum to aid the process of drug
target identification and distinction between targets sui-
table for prophylaxis, therapy or both. For this purpose,
available resources were browsed to construct a multi-
compartment metabolic network as complete as cur-
rently possible. The resulting set of biochemical reac-
tions and transport processes was adapted to obtain a
consistent network, which was validated by flux balance
simulations to fulfill metabolic processes, such as hemo-
globin digestion, that are known from the literature to
occur in P. falciparum. Subsequently, a modified version
o ft h em e t h o dp r o p o s e db yS h l o m iet al. [25] was
applied to calculate metabolic flux distributions specific
for the individual life cycle stages with respect to the
expression status of corresponding genes. In addition,
in silico knock-out studies were performed with flux bal-
ance analysis to identify metabolic reactions that are
essential for parasite development. This approach out-
performed the previously proposed choke-point analysis
[23,24] in terms of specificity, accuracy and precision
when evaluated with a set of known targets. Predicted
target reactions were further examined with regard to
homology to human enzymes, functional similarity to
therapeutic targets in other organisms and their pre-
dicted suitability for prophylaxis and disease treatment.
Results
Compilation of metabolic networks for P. falciparum and
human erythrocytes
A metabolic network for P. falciparum has been com-
piled in a semi-automated manner based on data from
the online databases Malaria Parasite Metabolic Path-
ways (MPMP) [26], BioCyc [27], KEGG [28], Reactome
[29], BRENDA [30], and the Transport Classification
Database [31]. Subsequently, the compiled metabolic
network was tested for consistency. This procedure
ensured among others that there are no reactions with
generic stoichiometry and no reaction duplets. In order
to link related reactions, corresponding metabolites
were ensured to have the same level of specificity. For
example, highly specific metabolites such as a-D-Glu-
cose were replaced by a more general metabolite (D-
Glucose) if both forms existed within the network. The
f u n c t i o n a l i t yo ft h i sn e t w o r kw a st e s t e db yu s i n gf l u x
balance analysis (FBA) to calculate flux distributions
that produce metabolites thought to be important for
parasite development, including phospholipids, amino
acids, nucleotides and cofactors. In this context Min-
Modes [32] were calculated for each of these metabo-
lites, which are basically minimal steady state flux
distributions that allow for the production of a certain
metabolite. In case no MinMode could be calculated,
i. e. no path exists that converts external nutrients into
the metabolite of interest, precursors of the metabolite
(as defined by metabolic maps of KEGG and MPMP)
were consecutively checked with respect to their produ-
cibility until one was found that is producible, thus
revealing missing reactions and transporters. Endpro-
ducts and intermediates of pathways known from the
literature to occur in P. falciparum, e. g. glycolysis, pen-
tose phosphate cycle, hemoglobin degradation and glu-
tathione conjugate export, were examined in the same
way. This process revealed that mostly intracellular
transporters were missing in the network that results
from the data of the different sources. Reactions that
had to be added include tRNA ligases in the mitochon-
drion and apicoplast, DNA and protein synthesis reac-
tions, and the biosynthesis of un-saturated fatty acids.
The resulting metabolic network is available in SBML
format (see Additional file 1 and Table 1 for more
details).
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is integrated into its natural environment, we decided to
additionally compile the metabolic network for the
human erythrocyte, which is the best studied system
among the host cells due to its reduced metabolic capa-
city and relatively simple availability. For the erythrocyte
multiple metabolic networks have been published that
comprise the cell’s core metabolism, including glycolysis,
pentose phosphate pathway, glutathione metabolism and
adenine nucleotide metabolism (see [33,34] and con-
tained references). However, these networks lack meta-
bolic pathways providing cofactors such as thiamin
diphosphate and pyridoxal phosphate that are required
for full cellular function. Therefore, we compiled the
metabolic network for human erythrocytes from avail-
able online resources to obtain a network that is as
complete as possible. As a main source served the
enzyme database BRENDA [30], from which all EC
numbers were extracted that are assigned to enzymes of
human erythrocytes. Furthermore, the human red blood
cell database [35], which catalogues the proteome of
human red blood cells, was queried for enzymes and
their EC numbers to complement those obtained from
BRENDA. Subsequently, the EC numbers were used to
extract reactions from the KEGG database. Transport
processes were added as suggested by the Malaria Para-
site Metabolic Pathways website [26] as well as from lit-
erature [36-50]. The network was subsequently checked
for its consistency and its ability to produce essential
metabolites as described above (see Table 1 for further
details and Additional file 2 for SBML file).
Life cycle gene expression profiles
This work intends to deduce stage-specific metabolism
for all stages of the life cycle of P. falciparum on the
basis of gene expression profiles. Since especially the
liver stage in the human host is experimentally difficult
to assess, we additionally analyzed gene expression data,
covering the full life cycle of P. yoelii ac l o s er e l a t i v eo f
P. falciparum causing malaria in rodents. Metabolism
predictions based on these expression data are assumed
to give an insight into the metabolic behavior of P. falci-
parum for those stages lacking large scale expression
profiling. Gene expression data has been gathered from
five publications (see Additional file 3): (a) a genome-
scale transcriptome analysis of P. falciparum covering
every hour of the intraerythrocytic developmental cycle
(IDC) by Bozdech et al. [5], (b) a genome-scale
transcriptome analysis including nine time points of P.
falciparum blood stage (early and late ring stage, early
and late trophozoite, early and late schizont, merozoite,
and gametocyte) and mosquito stage (salivary gland
sporozoite) by Le Roch et al. [6], (c) a cDNA library
obtained from liver stage expression analysis of the
rodent malaria pathogen P. yoelii 40 hours post infec-
tion by Sacci et al. [7], (d) a data set from Tarun et al.
[9], including seven samples extracted from P. yoelii,
covering three time points during the liver stage (24 h,
40 h, and 50 h post-infection), two time points during
the mosquito stage (10 days (midgut) and 15 days (sali-
vary gland) after blood meal), and two samples from
blood stages (schizont and mixed blood stages), and (e)
a genome-scale transcriptome analysis by Daily et al. of
43 samples derived from the blood of P. falciparum
infected patients which contain mostly ring stages of the
parasite [8].
In a first step, the accordance of these data sets was
checked for corresponding stages. For this purpose the
expression status was determined for each gene of every
expression sample as described in the Methods section.
Differences between the gene expression samples were
then assessed with a simple and intuitive distance mea-
sure, the normalized Hamming distance, which gives for
two strings of equal length the rate of positions at
which the corresponding symbols are different:
dist x y
xi yi
i
(,) =
∑ ≠
∑
1
1
In our case the symbols are binary values describing
the expression state of a gene (1: gene is expressed; 0:
gene is not expressed) and thus the numerator is the
sum of genes with different expression status and the
denominator is the total number of common genes in
two samples. The resulting Hamming distance matrix
for all gene expression sample pairs is shown in Addi-
tional file 4.
The distance matrix reveals that samples of the same
data set covering consecutive time points tend to be
more similar compared to those covering non-consecu-
tive time points, especially samples of the Bozdech or
the Le Roch data set. Furthermore, similar gene expres-
sion patterns can be observed for samples of different
data sets that correspond to the same life cycle stage,
e. g. Le Roch ring stage samples and Bozdech samples
extracted during hour 1 to 20 after erythrocyte infection.
Table 1 Overview of assembled metabolic network for P. falciparum and the human erythrocyte
Organism Reactions Transporters Metabolites Genes Compartments
Plasmodium falciparum 998 377 1622 579 6
Human erythrocyte 349 88 566 - 1
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observation by Daily et al. that the in vivo ring stage
expression samples can be ascribed to three clusters [8]:
starvation response accompanied by metabolism of
alternative carbon sources (cluster 1), active growth
based on glycolytic metabolism (cluster 2) and environ-
mental stress response (cluster 3). The distance matrix
confirms that samples of the same clusters are more
similar in terms of expressed enzymes. Only a fraction
of cluster 3 samples exhibits similarity to cluster 1 sam-
ples. Moreover, it shows that samples of cluster 2 are
similar to those samples of the Bozdech and Le Roch
data sets which correspond to early or very late blood
stages. In general, Hamming distances are larger when
samples belong to different data sets. This can be
ascribed to one or more of the following issues (i) differ-
ent methods have been used to analyze gene expression
(microarray analysis vs. cDNA library), (ii) experiments
are conducted with different organisms (P. falciparum
vs. P. yoelii) and (iii) for the individual data sets different
criteria have been applied to classify genes as absent or
present.
Gene expression data mapped onto metabolic pathways
Mapping gene expression data onto metabolic networks
may uncover active pathways for each stage and meta-
bolic differences between the individual life cycle stages.
In this context, we calculated the ratio of expressed
genes per pathway (as defined by KEGG) for each gene
expression sample. This ratio was then used to group
pathways with respect to co-expression of involved
enzymes to detect whether there are patterns in the
activity of pathways as a function of the individual
developmental stages. Since the blood stage is the only
phase covered by all data sets, samples extracted during
the IDC were used to cluster the pathways (see Addi-
tional files 5, 6 and 7).
Three pathway clusters can be identified for the Boz-
dech and the Le Roch data sets, which roughly corre-
spond to each other (see green, blue, and yellow bar in
Additional file 5 and 6). The green clusters, which have
10 pathways in common (e.g. glycolysis, glyceropho-
spholipid metabolism and porphyrin metabolism), con-
tain pathways where only a fraction of pathway
associated genes are expressed during the IDC with a
maximum of expressed genes during late trophozoite
and early schizont stage. Pathways associated with the
blue clusters (common pathways: fatty acid biosynthesis,
lipoic acid metabolism, vitamin B6 metabolism and one
carbon pool by folate metabolism) show gene expression
almost exclusively during late trophozoite and early
schizont stages of the IDC, while those of the yellow
clusters (common pathways: pentose phosphate path-
way, inositol phosphate metabolism) exhibit many
expressed genes during all phases of the intraerythrocy-
tic developmental cycle. Notably, during the gametocyte
stage (Le Roch data set) a high number of genes are
expressed in all pathways and in contrast only few genes
during the invasive stages (Le Roch data: sporozoite,
merozoite). Pathway clusters as described above for the
blood stage are not as apparent for the Tarun data,
since this stage has not been analyzed as detailed.
Nevertheless, certain pathways group together as seen
for the Bozdech and Le Roch data sets (see colored bars
in Additional file 7). Daily and coworkers found that
their ring stage expression samples can be divided into
three clusters: starvation response accompanied by
metabolism of alternative carbon sources (cluster 1),
active growth based on glycolytic metabolism (cluster 2)
and environmental stress response (cluster 3). These
clusters can be found as well when expression samples
are mapped to metabolic pathways as shown in Addi-
tional file 8. In samples of cluster 1 almost all enzymes
are expressed in each of the considered pathways, sug-
gesting that required metabolites cannot be obtained in
sufficient amounts from the host and thus the parasite
has to activate all possible pathways in order to obtain
these metabolites. In contrast, less enzymes are
expressed in samples corresponding to cluster 2. Here,
enzymes of sugar metabolism related pathways like gly-
colysis, pentose phosphate pathway and glycerophospho-
lipid metabolism (blue bar) are mostly activated. Similar
expression patterns can be observed for cluster 3 sam-
ples. However, more enzymes are expressed in certain
pathways such as fatty acid synthesis, thiamine metabo-
lism and ubiquinone biosynthesis (pink bar).
In general, the majority of metabolic pathway genes is
expressed during starvation (Daily data) or late tropho-
zoite and early schizont stage where reproduction of
biomass is at its peak [43]. Pathways showing similar
patterns of activation and suppression are presumably
co-regulated. Especially in the case of purine and pyri-
midine biosynthesis this is plausible, since both nucleo-
tide types are needed in large amounts at the same time
during DNA replication and mRNA synthesis. Likewise
the expression of genes associated with fatty acid bio-
synthesis, pyruvate metabolism, and lipoic acid metabo-
lism seems to be coupled, since only few genes are
expressed during blood stages but significantly more
during liver stages. Most of the reactions assigned to
these three KEGG pathways are assumed to take place
in the apicoplast and are linked to each other. When
fatty acid demand is fully satisfied by import, which is
suggested for the blood stage by findings of Vaughan et
al. [51], neither the precursor acetyl-CoA (pyruvate
pathway) nor lipoic acid, a co-factor of pyruvate dehy-
drogenase catalyzing acetyl-CoA synthesis, are needed
within the apicoplast. Thus, it seems reasonable that
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sidering the Bozdech dataset, are co-regulated.
Metabolic flux predictions for different life cycle stages
Gene expression data give an impression of the meta-
bolic status of a cell, as has been shown in the previous
section. However, gene expression data alone are not
sufficient to deduce metabolic fluxes. Simply assuming a
correlation between gene expression levels and meta-
bolic fluxes is not appropriate, since it has been shown
that neither mRNA levels and protein levels always cor-
relate well [52,53] nor enzyme levels and corresponding
flux rates of catalyzed reactions [54,55]. Furthermore,
expression data is not always available for all genes of
interest, or in some cases, there are no genes assigned
to metabolic reactions at all, if they are rather inferred
from metabolic context than based on direct biochem-
ical evidence. In addition, from gene expression data
alone no information can be gained with regard to
which nutrients are imported into the cell and which
metabolites are secreted. Flux balance approaches pro-
vide a means to predict flux distributions despite such
obstacles. Flux values can be predicted even for those
reactions where no gene expression data is available, as
fluxes are not independent due to the assumed steady
state condition, which requires the sum of fluxes produ-
cing a metabolite to equal the sum of fluxes consuming
it. A reasonable objective function describing the cellu-
lar goals is essential to obtain meaningful flux distribu-
tions with FBA. In the case of P. falciparum the overall
goal is reproduction, and thus biomass production on
the metabolic level. At the same time the parasite has
an interest to keep its host cell alive for the period of
replication which sets an upper limit on the replication
rate. Depending on how well the organism of interest is
already studied, the objective function might neglect
certain metabolically important issues, e. g., a metabolite
essential for reproduction that has not been noticed yet.
On this account, we decided to apply an approach that
combines FBA and gene expression information to cal-
culate flux distributions for the different parasitic life
cycle stages. The integration of expression data ensures
that metabolic aspects not captured by our objective
function are nevertheless represented in the calculated
flux distributions. Our approach is based on a FBA
approach proposed by Shlomi et al. [25], which maxi-
mizes the number of reactions whose activity is consis-
tent with the expression state of the corresponding
genes. We made several modifications to this technique
(see Figure 1): (a) Constraints were added to ensure the
production of important biomass precursors such as
phospholipids, which are needed for parasite reproduc-
tion (see Additional file 9). These target metabolites
might vary depending on the stage covered by the given
gene expression sample. DNA synthesis is important for
stages aiming at reproduction, like trophozoites. In con-
trast, for invasive forms of the parasite (sporozoite, mer-
ozoite, etc.) this is not an issue and therefore not
considered in flux calculations corresponding to these
stages. Furthermore, blood stages need to incorporate
heme from hemoglobin degradation into hemozoin
molecules in order to prevent intoxication and cell lysis.
This makes hemozoin a target metabolite for these
stages, but not for liver or mosquito stages where hemo-
globin is not present. Targeted deletions of critical fatty
acid synthesis enzymes in P. yoelii and P. falciparum
suggest that fatty acid synthesis in the apicoplast is only
essential during late liver stage [51]. This implies that
pyruvate dehydrogenase (PDH), which provides fatty
acid synthase with acetyl-CoA, is not essential during
any other stage and thus lipoate, a cofactor of PDH, is
as well dispensable in the apicoplast. Since PDH is the
only enzyme in the apicoplast that requires lipoate, we
demanded lipoate biosynthesis in this organelle only
during late liver stage. (b) Constraints were added to
minimize the number of active reactions whose exis-
tence is not supported by genome annotations. This is
useful as especially data from the BioCyc database con-
tain reactions without any associated gene that are
nevertheless declared to be present in P. falciparum to
fill gaps in pathways. (c) The original approach proposed
by Shlomi et al. seeks all reactions catalyzed by the
same enzyme to be simultaneously active if the corre-
sponding enzyme is expressed. As this might not always
be appropriate, our method only tries to assign a non-
zero flux to at least one of these reactions. (d) The net-
work is forced to fulfill its tasks with a minimal amount
of externally supplied metabolites to account for the
limited amount of nutrients available in the host cell
that has to be shared among the offspring. More details
about the approach are provided in the Methods
section.
The approach was applied to each of the gene expres-
sion samples extracted from different time points of
parasite development (see Additional file 3) to predict
respective metabolic fluxes during these time points. In
order to compare the resulting flux distributions for the
individual time points, normalized Hamming distances
were computed for all flux distribution pairs (see Addi-
tional file 10). In general, the calculated flux distribu-
tions are more similar to each other (max. Hamming
distance: 0.188) than the corresponding gene expression
samples (max. Hamming distance: 0.718). However,
similarity patterns as observed for the gene expression
data are also detectable for the flux profiles. For exam-
ple, flux profiles corresponding to consecutive time
points during the blood stage are more similar than
those of non-consecutive time points (see Bozdech data;
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Page 5 of 27Figure 1 Illustration of presented flux balance approach to predict life cycle specific metabolism. Given the gene expression data (blue
table) flux distributions (red arrows) within the shown example metabolic network (blue arrows) can be inferred for time points t1 and t2 as
depicted in (A). However, neither flux direction nor flux strength can be deduced from gene expression alone (indicated by question marks next
to flux arrows). The set of all possible flux distributions that are consistent with the gene expression data can be reduced by knowledge about
target fluxes such as biomass production (i). Reactions that are not supported by genome annotation might represent errors in the network
assembly. Therefore it is desirable to prevent the usage of such reactions in calculated flux distributions (ii). An enzyme or a transporter that is
able to process different metabolites does not necessarily convert all substrates at same rates. If one reaction product is not converted further by
subsequent enzymes, it accumulates and as a consequence the net production rate is close to zero, even if the gene is expressed and substrate
is available (iii). The flux solution space can be narrowed down further when assuming that biomass production is achieved with a minimal
amount of nutrients (iv), which are of varying availability (v). Gene products can be present within a cell, even when the gene transcript is not
detectable, as proteins appear later than the corresponding mRNA and protein degradation might be delayed compared to mRNA degradation.
Considering proteins to be present whose transcript was detectable during a previous time point (vi) presumably reflects the actual cellular
status better than taking only the current transcription snapshot into account. The flux distribution calculated by our flux balance approach,
which incorporates all these issues, is shown in (B).
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sponding to in vivo expression profiles of the same clus-
ter tend to be more similar than those of different
clusters.
As experimental data on intra-parasitic fluxes are not
available, we checked the plausibility of calculated flux
distributions by comparing predicted exchange fluxes
between host and parasite with available experimental
observations.
Metabolite exchange with host
During its life cycle, P. falciparum is exposed to differ-
ent environments in its hosts (human liver, human ery-
throcyte, mosquito gut, mosquito salivary gland) and
thus has to deal with different nutrient supply. It has
been shown for Trypanosoma brucei [56] that this para-
site is able to remodel its metabolism depending on
available carbon sources. It is very likely that P. falci-
parum utilizes likewise varying parts of its enzyme
equipment as a function of available nutrients, which
results in different sets of metabolites transported
through the parasite’sp l a s m am e m b r a n ed u r i n gt h e
individual developmental stages.
Additional file 11 gives an overview of imported (red)
and excreted (green) metabolites during the individual
life cycle stages, as predicted by our FBA method when
considering only the metabolic network of the parasite,
without any further information about the parasite’s
environment. Glucose, the main energy source for P. fal-
ciparum during the IDC, is converted via glycolytic
enzymes to lactate, which is then excreted [57]. This
phenomenon is recovered by our simulations for most
of the samples extracted during the blood stage. For
multiple gene expression samples amino acids are pre-
dicted to be exported, which contrasts the naive
assumption that all available amino acids are needed for
protein biosynthesis. In fact, the parasite digests up to
three quarters of the host hemoglobin during the IDC
to provide amino acids for protein synthesis, to gain
space in the host cell for further growth [58] and to
maintain the osmotic stability of the host cell [59].
Excess amino acids not incorporated into the parasite’s
proteome are exported out of the infected host cell [60]
and is therefore in accordance with the predictions.
Experiments have shown that P. falciparum relies on
exogenous supply of isoleucine, the only amino acid that
is not present in hemoglobin [61]. For all blood stage
related samples isoleucine uptake has been correctly
predicted. Moreover, in concordance with experiments
by Kirk and Saliba [62], coenzyme A precursor pan-
tothenate is imported in all our simulations. According
to our predictions the parasite satisfies its demand for
NAD+ precursors mostly with the import of nicotina-
mide, but also with nicotinate import, which is
consistent with experimental findings [43] that suggest
P. falciparum to be dependent on exogenous supply of
these metabolites. The parasite possesses an antioxidant
defense system, which involves glutathione to eliminate
peroxides and toxic substances resulting in the forma-
tion of glutathione disulfate and glutathione conjugates
that are subsequently either regenerated or removed
from the cell [63]. All predicted flux distribution cor-
rectly suggest the export of glutathione conjugates.
However, there are predicted transport processes that
are not in agreement with literature knowledge. For
example, phosphate is mostly predicted to be exported,
while it is reported to be taken up [64]. Likewise, ATP
is imported rather than exported to support the host as
proposed by Kanaani and Gins-burg [65] and hemoglo-
bin is predicted to be taken up during liver stages where
no hemoglobin is present. Furthermore, purine precur-
sors are imported mostly in the form of inosine, while
hypoxanthine is exported, despite being available in
higher concentrations in the blood plasma than the
other purine precursors. These discrepancies indicate
that the applied model, which assumes that all nutrients
are available without limits, is not appropriate and thus
further constraints reflecting the parasites metabolic
environment are needed in order to obtain more reliable
flux predictions.
Improved metabolic flux predictions for parasitic blood
stage
A model which does not define the parasite’se n v i r o n -
ment might results in certain incorrect predictions as
has been shown in the previous section. Therefore, we
tried to improve predictions by integrating additional
information about the parasite’s host and available nutri-
ents. These improvements could only be implemented
for the blood stage of the parasite to which most of the
current knowledge about the malaria pathogen corre-
spond due to its simple experimental accessibility and
the fact that among the host cells the erythrocyte is the
best studied system. We combined the parasite’s meta-
bolic network with that of the erythrocyte and forced
the combined network to produce in addition metabo-
lites important for erythrocyte metabolism. Furthermore,
constraints reflecting knowledge about the blood stage
were incorporated into the calculations. For example,
the parasite was forced to consume at least a certain
amount of hemoglobin and glucose, since both metabo-
lites are known to be consumed by the parasite in large
amounts [62,66]. Up-take limits were set for several
metabolites, including purine precursors, sugars, cofac-
tors and phospholipid headgroup precursors, which are
proportional to the respective blood plasma concentra-
tions as listed in the Human Metabolome Database
http://www.hmdb.ca/. In addition, constraints were
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as choline and ethanolamine within the parasite due to
phosphorylation [67,68]. Observations by Mehta et al.
[69] indicate that P. falciparum is able to repress glyco-
lysis of erythrocytes by inhibiting their glycolytic
enzymes phosphofructokinase and pyruvate kinase. In
concordance with these observations both host enzymes
were inhibited in flux calculations that correspond to
stages subsequent to the ring stage of the IDC.
For a certain fraction of P. falciparum genes, the tran-
scriptome was found to correlate better with the pro-
teome of the following than the current stage [70]. For
this reason, considering only the gene expression snap-
shot of a single time point does not give a complete pic-
ture on the actual present proteome. Including the gene
expression status of previous time points into the calcu-
lations should therefore further improve flux predic-
tions. We modified our algorithm in such a way that
genes were considered to be expressed, if a transcript is
either present during the time point of interest or dur-
ing a time span of approximately 12 hours prior to this
time point (concerns 12 preceding samples of Bozdech
data set and 2 preceding samples of Le Roch data set).
Since the time intervals between samples covering the
l i v e ro rt h em o s q u i t os t a g ea r elarger, this modification
was only applied to flux predictions for the blood stage.
Metabolites predicted to be exchanged between host
and parasite when using the improved algorithm (com-
bination of host and parasite network, additional con-
straints reflecting knowledge about the blood stage as
well as consideration of gene expression status of pre-
ceding time points; see Additional file 12) are in consid-
erably better accordance with experimental findings (see
Figure 2 and Table 2) than before. In contrast to the
previous predictions derived from the unmodified algo-
rithm, purine precursors and choline are only imported
and not secreted, while proteinogenic amino acids
(except for isoleucine) are only exported. In our flux cal-
culations hemoglobin is assumed to be digested at
higher rates during trophozoite and schizont stages of
the IDC, which releases iron that can be utilized by the
parasite [71-73]. When the host’s glycolytic enzymes
phosphofructokinase and pyruvate kinase are inhibited
(trophozoite and schizont stages), ATP can no longer be
obtained from the host. Thus, the parasite needs to pro-
duce more ATP on its own, which requires the import
of additional phosphate. Moreover, in order to ensure
host survival for a certain time period the parasite pro-
vides the host with ATP, which is in accordance with
findings by Kanaani and Ginsburg [65].
In general, flux profiles derived from in vitro (Bozdech and
Le Roch data set) and in vivo gene expression samples
(Daily data set) are fairly similar in terms of exchanged
metabolites between host and parasite, especially those
corresponding to the active growth like cluster (cluster 2).
One main difference is that more purine precursor types
are predicted to be imported for the in vivo samples. The
main differences between in vivo clusters is the absence of
predicted fatty acid and choline import for samples of the
starvation like cluster (cluster 1). This could be attributed
to environmental conditions that result in a lack of nutri-
ents required for parasite growth. Cell membrane produc-
tion is then either not possible or not the main focus and
thus the import of membrane precursors like fatty acids
and choline is not required.
There are still some metabolites whose predicted
transfer direction through the parasite’sp l a s m am e m -
brane does not meet literature knowledge. For example,
it has been found that arginine contained in the medium
is imported and depleted by the parasite, resulting in
ornithine which is then excreted [43]. In contrast, our
simulations suggest arginine export. Since these observa-
tions were made at excessively high arginine concentra-
tions, further experiments are needed to examine
arginine transport under physiological conditions. Our
predictions are more in line with experiments by Liu et
al. [61] which indicate that hemoglobin degradation
satisfies the parasite’s demand for all amino acids during
the blood stage except for isoleucine and thus isoleucine
is the only amino acid required to be taken up. Other
predicted metabolite transports that contradict literature
knowledge are those of formate, hydrogen-carbonate
and ethanolamine. Almost no transport is predicted for
ethanolamine, because the transport process is not asso-
ciated with any gene and therefore our algorithm avoids
to assign non-zero fluxes. However, this is not the case
for formate and hydrogen-carbonate, but rather missing
reactions and transport processes in the erythrocyte that
are needed to dispose of these metabolites. Thus, pre-
dictions can still be further improved when more knowl-
edge is available on the particular developmental stages
as well as the host cell.
Counting for each metabolic reaction and transport
process in how many stage-specific flux distributions it
is predicted to be active when using the improved algo-
rithm (see Additional file 13), reveals that nearly 350
reactions carry a non-zero flux in all 96 flux profiles
that are derived from gene expression samples extracted
during the IDC. In comparison to these globally active
reactions, others that are present during fewer time
points can be considered as more stage-specific.
Calculated fluxes mapped onto metabolic pathways
In order to explore the predicted flux distributions
derived from the improved algorithm on the level of
metabolic pathways, we again performed a mapping.
This time, instead of counting expressed genes per
KEGG pathway, we counted reactions carrying non-zero
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wether there are changes during the IDC (see Additional
files 14, 15 and 16). Due to the integration of gene
expression states of preceding time points into the cal-
culations more enzymes are considered to be present
than are suggested by the gene expression sample of the
time point of interest. In general, for consecutive time
points of gene expression sample extraction the number
of active reactions per pathway does not vary as much
as the number of expressed genes per pathway (compare
to Additional files 5 and 6). Therefore, fewer metabolic
changes are predicted over the course of the IDC than
are suggested by the gene expression data. Nevertheless,
time dependent activity variation can be observed for
certain pathways. For example, fewer reactions corre-
sponding to folate biosynthesis are predicted to be active
during the ring stage than during subsequent stages. In
contrast, for the citric acid cycle as well as sphingolipid
metabolism an increase in active reactions is predicted
during schizont and early ring stage.
Figure 2 Predicted host parasite metabolite exchanges using improved algorithm. Flux distributions have been predicted with our
improved flux balance approach (see Figure 1) for each time point of the intraerythrocytic developmental cycle for which a gene expression
profile exists. Simulations were conducted on the basis of the combined metabolic network of parasite and host and additional constraints
reflecting knowledge about the blood stage. Furthermore, the expression status of genes during preceding time points was considered for the
flux calculations. Resulting metabolite exchanges between host and parasite are depicted in this figure. Red matrix entries represent metabolites
that are predicted to be imported into the parasite, while green matrix entries represent metabolites secreted into the host compartment.
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ples show mainly similar pathway activity levels. Sam-
ples of the starvation-like cluster (cluster 1) vary from
the others only with respect to lipid metabolism related
pathways, which have a higher fraction of active reac-
tions (especially the fatty acid biosynthesis pathway),
and energy metabolism. Less reactions of the glycolytic
pathway are active while more reactions of the citric
acid cycle are active compared to cluster 2. The same
holds true for some samples of the stress response-like
cluster (cluster 3).
However, for some pathways the flux distributions
vary substantially from the reported expression profiles.
For instance, according to our flux predictions synthesis
of terpenoids (part of steroid synthesis pathway) takes
place during the complete IDC, while gene expression
data suggest this pathway to be active only during the
second half of the IDC. This is due to the chosen set of
target metabolites required to be produced during the
individual stages (see Additional file 9), which includes
isopentenyl diphosphate. This might not be appropriate
for all time points.
Determination of fluxes with higher reliability
For each stage of the parasite’s developmental cycle,
we determined so-called consensus reactions that are
predicted to be active for all gene expression samples
covering the same stage. These reactions are more
likely to actually occur during a certain stage, since
they are derived from different data samples. In order
to identify consensus reactions we grouped all calcu-
lated flux profiles into 13 sets (LS24, LS40, LS50,
eRing, lRing, eTropho, lTropho, eSchiz, lSchiz, Mero,
Gameto, ooSporo, sgSporo; see Additional file 3) with
respect to represented stages and determined those
reactions that carry a non-zero flux in all flux profiles
of the same set. For all stages of the intraerythrocytic
developmental cycle those flux profiles were consid-
ered that were calculated with the improved
algorithm.
Table 2 Metabolite exchanges between parasite and host: prediction vs. experiment
Metabolite Predicted Experiment Comment References
Glucose Uptake uptake [57,128,129]
Lactate Secretion secretion [57,128,129]
Hemoglobin uptake uptake [57,128]
Amino acids Secretion secretion [57,128,129]
Isoleucine uptake uptake [57,128,129]
Nucleosides/nucleobases uptake uptake [128-130]
Choline uptake uptake [68,128,129,131]
Ethanolamine almost no
exchange
uptake No gene assigned to ethanolamine transporter [128,132]
Phosphatidylethanolamine uptake uptake [128,132]
Phosphatidylserine uptake uptake [128]
Phosphate uptake uptake [64,128,129]
Pantothenate uptake uptake [62,128,129]
Nicotinamide/nicotinate uptake uptake [43,128]
Folate uptake uptake [128,129]
4-aminobenzoic acid uptake uptake [128,129]
ADP uptake/secretion uptake secretion in early blood stage when ATP can still be salvaged from
host
[65,128,129]
ATP uptake/secretion secretion uptake in early blood stage when host glycolysis is not repressed
yet
[65,128,129]
Glycerol uptake/secretion uptake/
secretion
[128,129]
Glutathione conjugate secretion secretion [63,128,129]
Ornithine mostly secretion secretion [43]
Cholesterol uptake uptake [128]
Formate no exchange secretion Erythrocyte lacks reactions and transport processes to dispose of
metabolite
[128,129]
Fe2+ no exchange/
uptake
uptake [128,129]
H+ Mostly secretion secretion [128,129]
HC03- no exchange secretion Erythrocyte lacks reactions and transport processes to dispose of
metabolite
[128,129]
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fraction of consensus reactions per total number of
pathway reactions was computed to uncover the distri-
bution of consensus reactions among pathways (see
Additional file 17). To get an impression of how many
consensus reactions are shared between the different
stages, this fraction was also computed for those con-
sensus reactions that two sets have in common. In sev-
eral pathways the same reactions are active during the
whole IDC (e. g. ubiquinone biosynthesis and terpenoid
biosynthesis). These are mostly biosynthesis pathways
where alternative routes are rare and the endproducts
are considered to be essential. Therefore, the network is
forced to produce them, which results in a large overlap
between the predicted fluxes through these pathways for
all time points. By contrast there are pathways where
more accordance can be observed for trophozoite and
schizont stages (e.g. glutathione metabolism, pentose
phosphate pathway). This is mainly due to the fact that
consensus reactions for the early and late ring stage are
derived from many more samples than those for other
stages. Especially the heterogeneous in vivo expression
samples contribute to a low number of consensus reac-
tions for these stages. The citric acid cycle is one of the
few pathways where a certain level of agreement exists
between ring and schizont stages.
Search for essential reactions as potential drug targets
Beside the prediction of stage-specific metabolic fluxes
the goal of this work is the identification of novel drug
targets in Plasmodium falciparum. For this purpose flux
balance simulations were conducted to analyze the com-
piled metabolic network with regard to essential reac-
tions required for the production of important cellular
metabolites. Enzymes catalyzing such reactions represent
potential drug targets, since their inhibition would result
in a shortage of required metabolites and thereby in
impaired development. Knock-outs were simulated with
a simple FBA approach neglecting gene expression
information. No assumptions were made about the cel-
lular environment and nutrient uptake was not
restricted, since such information is not available for all
stages. Reactions were successively constrained to carry
no flux, while the network was forced to produce all
metabolites that are assumed to be essential during any
developmental stage (all metabolites listed in Additional
file 9). If no solution could be found to this problem the
reaction was assumed to be essential. For more details
see the Methods section. As not all metabolites are
equally important during all time points of parasite
development, e. g. DNA building blocks are not required
to be synthesized during the merozoite stage, a reaction
detected by this means might not be globally essential,
but rather during those time points when the particular
metabolite requiring the activity of the reaction is indis-
pensable. On the other hand, certain reactions that are
not detected as essential might be incorrectly classified,
if nutrients are actually not available in sufficient
amounts during all time points, which conflicts the
simulation assumption. In this case essential metabolites
cannot be derived from imported precursors, but rather
need to be completely synthesized, making additional
reactions indispensable. Thus, all reactions identified as
essential by this approach are essential during at least
one developmental stage, but not all reactions that are
essential during any stage are necessarily recovered. To
evaluate our results we used as our gold standard a set
of 57 enzymes that were shown to have antimalarial
effects upon inhibition or silencing (see Table 3).
The simulations identified 307 reactions that are
essential for the parasite. This set includes reactions
that correspond to 35 enzymes of our gold standard
(see Table 3). Blocking all reactions catalyzed by the
same gene product recovers two more targets (dihy-
drofolate reductase and hypoxanthine phosphorribosyl-
transferase) contained in our gold standard. Among
the 20 remaining enzymes 13 are detected as essential
by our method, if additionally transporters are con-
strained that import biomass precursors bypassing the
respective enzyme. For example, inhibition of the sper-
midine transporter makes the spermidine synthase
indispensable. These enzymes are therefore either not
metabolically essential during all environmental condi-
tions but only during those stages where particular
nutrients are not present in sufficient amounts, or the
respective parasitic transporters are not efficient
enough. Furthermore, GMP synthase is detected if the
import of guanine and guanosine is constrained and all
reactions catalyzed by the enzyme are blocked.
Ornithine decarboxylase is not found by our method,
as a an alternative path exists to synthesize putrescine
involving carbamoylputrescine amidase. Blocking this
enzyme in addition to the spermidine and putrescine
transporters makes ornithine decarboxylase indispensa-
ble. Carbamoylputrescine amidase is very likely not
present in P. falciparum, since it was added in the Bio-
Cyc database to fill gaps in the putrescine biosynthesis
pathway of which only one enzyme is associated with a
gene. Succinate dehydrogenase and NADH dehydro-
genase, which are not even detected when nutrient
import is limited, are very likely false positives. For
both enzymes of the mitochondrial electron transport
chain antimalarial activity was demonstrated through
inhibition with substrate analogs of ubiquinone [74,75].
As ubiquinone, the substrate of both enzymes, can be
provided with electrons by several enzymes (succinate
dehydrogenase, NADH dehydrogenase, dihydroorotate
dehydrogenase, FAD-dependent glycerol-3-phosphate
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not quite obvious why inhibition of only one enzyme
should result in impaired parasite development. One
explanation could be that the ubiquinone analogs do
not only inhibit one enzyme, but also others that use
ubiquinone as a substrate. This is supported by the
findings of Painter et al. [76], who discovered that an
active mitochondrial electron transport chain might
only be required for the disposal of electrons derived
from dihydroorotate dehydrogenase, an essential
enzyme for pyrimidine biosynthesis. They showed that
parasites that express the corresponding yeast enzyme,
which does not require ubiquinone as an electron
acceptor, are insensitive to atovaquone, an inhibitor of
the electron transport chain Complex III. This suggests
that the antimalarial effect of ubiquinone analogs is
rather due to either additional inhibition of the down-
stream Complex III or simultaneous inhibition of all
enzymes providing ubiquinone with electrons (includ-
ing dihydroorotate dehydrogenase), instead of the sole
inhibition of succinate dehydrogenase or NADH dehy-
drogenase. Our simulations indicate further-more that
neither sole inhibition of choline kinase nor sole inhi-
bition of phosphoethanolamine methyltransferase kills
the parasite, because phosphatidylcholine can be
derived from choline as well as from ethanolamine
[77]. The question remains whether these pathways are
indeed able to fully compensate the loss of the alterna-
tive pathway, as both have been suggested to affect
parasite growth [78,79]. However, the findings by
Choubey et al. [78] can also be explained by unspecific
inhibitor (analog of miltefosin) binding, resulting in
the inhibition of both choline kinase and phosphoetha-
nolamine methyltransferase [77]. Finally, the gold stan-
dard enzyme fructose-bisphosphate aldolase was not
detected by our knock-out simulations. Our simula-
tions do not confirm that aldolase is metabolically
essential, since ATP can be generated from glycerol-3-
phosphate (derived from imported glycerol) and glycer-
aldehyde-3-phosphate (produced in pentose phosphate
pathway), which enter glycolysis downstream of the
enzyme. These metabolites might yield lower amounts
of ATP though, due to the lower concentration of gly-
cerol in the blood compared to glucose. Buscaglia et
al. [80] demonstrated that aldolase bridges the actin-
myosin motor, which is involved in gliding motility
and host cell invasion, and an invasin protein that con-
nects to host cell receptors. Metabolite (and drug)
binding to aldolase prevents interactions between aldo-
lase and the invasin protein, which has negative effects
on motility and host cell infection. Therefore, the
observed reduction of parasitemia upon aldolase inhi-
b i t i o nm i g h tr a t h e rb ec a u s e db yi m p a i r e dh o s tc e l l
invasion than metabolic effects.
Evaluation of predicted drug targets
Previously, two methods have been presented to predict
drug targets in P. falciparum [23,24]. Both approaches
apply the concept of choke-points, which are reactions
that are the only source or sink for at least one metabo-
lite. Such reactions are assumed to be essential due to
an accumulation of potentially toxic metabolites or a
lack in required substrates upon inhibition. To compare
the performance of our method and that of choke-point
analysis, all choke-points were identified in the compiled
metabolic network and assessed with our gold standard
set of drug targets. 679 choke-point reactions were
detected in the network, including reactions that are
catalyzed by 37 enzymes of our gold standard. Thus,
choke-point analysis recovers more true targets than our
method. However, due to the large number of reactions
predicted as essential by the choke-point analysis, our
flux balance approach results in higher values for speci-
ficity, accuracy and precision and therefore a better
enrichment of true targets (see Figure 3). This means
that a choke-point analysis might end up detecting
more true targets, but our approach will result in a set
of predicted targets with a lower percentage of false
positives, which reduces the waste of experimental
resources needed to validate the predictions.
To address the question whether some of our pre-
dicted targets that are not contained in our gold stan-
dard are nevertheless valid targets, the SuperTarget
databases [81] was queried with the respective EC num-
bers to check whether some of these reactions are cata-
lyzed by enzymes that were previously targeted in the
course of medical treatments or were shown to have
effects on the viability of an organism or pathogenic
cell. Of 155 reactions that are assigned to genes and are
predicted to be essential but are not covered by the gold
standard enzymes, 39 correspond to enzymes that are
listed in the SuperTarget database as drug targets.
To avoid unwanted side effects within the human
host, it is beneficial to target parasitic enzymes not
homologous to human enzymes. Therefore, a BLAST
search was conducted on (non-redundant) human pro-
tein sequences using the predicted P. falciparum protein
sequences from PlasmoDB as queries. Analogous to [23]
we applied an E-value significance threshold of < 0.075
to determine homologous sequences. Of the 198 reac-
tions that are predicted to be essential and are assigned
to genes, 168 are catalyzed by enzymes that are homolo-
gous to human enzymes. The gene products catalyzing
the remaining 30 reactions represent presumably good
drug target candidates. Targets with human homologs
may still be interesting targets as long as binding sites
for potential inhibitors are sufficiently distinct.
As discussed above, reactions predicted to be essential
are not necessarily essential during all time points.
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EC Reaction Choke-
points
Found
by FBA
Comment Reference
1.1.1.205 IMP dehydrogenase Yes No Precursor import (adenosine, hypoxanthine, inosine) [133]
1.1.1.267 1-deoxy-D-xylulose-5-phosphate
reducetoisomerase
Yes Yes [84]
1.3.1.9 enoyl-ACP-reductase Yes Yes [134-136]
1.3.3.1 Dihydroorotate oxidase No Yes [92-95,137]
1.3.99.1 Succinate dehydrogenase No No Presumably unspecific off-target effects [75]
1.5.1.3 Dihydrofolate reductase No No Necessary to block all reactions catalyzed by the enzyme [138-140]
1.6.5.3 NADH dehydrogenase (ubiquinone) No No Presumably unspecific off-target effects [74]
1.8.1.7 glutathione reductase Yes Yes [141,142]
1.8.1.9 thioredoxin reductase Yes Yes [143,144]
1.10.2.2 cytochrome c reductase Yes Yes [145]
1.15.1.1 superoxide dismutase Yes Yes [146]
1.17.4.1 Ribonucleoside-diphosphate
reductase
No Yes [147-149]
2.1.1.100 Protein-S-isoprenylcysteine-O-
methyltransferase
Yes Yes [150,151]
2.1.1.103 Phosphoethanolamine methyltrans-
ferase
Yes No Presumably unspecific off-target effects [77,79]
2.1.1.45 Thymidylate synthase No Yes [152,153]
2.1.1.64 3-Demethylubiquinone-9,3-O-
methyltransferase
Yes Yes [154]
2.3.1.24 sphingosine-N-acyltransferase Yes Yes [155]
2.3.1.37 delta-aminolevulinate synthase Yes Yes [99,101]
2.3.1.41 3-Oxoacyl-[acyl-carrier protein]
synthase
Yes Yes [156,157]
2.3.1.50 serine-palmitoyl transferase No Yes [155]
2.4.2.1 Purine-nucleoside phosphorylase Yes No Precursor import (hypoxanthine, xanthine) [158]
2.4.2.8 Hypoxanthine
phosphoribosyltransferase
Yes No Necessary to block all reactions catalyzed by the enzyme [159-161]
2.5.1.15 Dihydropteroate synthase Yes No Precursor import (folate) [162-164]
2.5.1.16 Spermidine synthase Yes No Precursor import (spermidine) [165]
2.5.1.18 Glutathione transferase Yes Yes [166-169]
2.5.1.19 3-Phosphoshikimate 1-
carboxyvinyltransferase
Yes No Precursor import (4-aminobenzoate, folate) [170]
2.5.1.58 Farnesyl-diphosphate
Farnesyltransferase
No Yes [171]
2.7.1.32 Choline kinase No No Presumably unspecific off-target effects [78]
2.7.8.3 Ceramide-
cholinephosphotransferase
Yes Yes [155]
3.3.1.1 S-adenosyl-l-homocysteine
hydrolase
Yes Yes [172-175]
3.4.11.1 leucine aminopeptidase Yes No Precursor import (amino acids) [176]
3.4.14.1 dipeptidyl aminopeptidase 1 No No Precursor import (amino acids) [177]
3.4.23.38 plasmepsins (aspartic acid proteases) No No Precursor import (amino acids) [178,179]
3.4.23.39 plasmepsins (aspartic acid proteases) No No Precursor import (amino acids) [178,179]
3.5.1.89 N-acetyl glucosaminylphosphatidyli-
nositol deacetylase
No Yes [180]
3.5.2.3 dihydroorotase Yes Yes [96,137]
3.5.4.4 Adenosine deaminase Yes No Precursor import (hypoxanthine, inosine, xanthine) [181,182]
4.1.1.17 Ornithine decarboxylase No No Precursor import (spermidine, putrescine); alternative reaction
R01152
[183-185]
4.1.1.23 Orotidine-5’-phosphate
decarboxylase
Yes Yes [89-91,97,98]
4.1.1.50 Adenosylmethionine decarboxylase No No Precursor import (spermidine) [186]
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fluxes, which were predicted on the basis of gene
expression data, to get an idea during which stages reac-
tions are essential. In this context we mapped the con-
sensus reactions calculated in the previous section for
each life cycle stage (reactions that carry a non-zero flux
in all flux profiles corresponding to the same life cycle
stage) onto the set of essential reactions (see Additional
file 18). This mapping gives a hint on targets that are
present during all time points as opposed to those that
are only active during certain stages. Depending on the
time point when a reaction of the latter type is essential,
drugs designed to inhibit the respective enzyme can
either be applied as prophylactic drugs to kill the liver
stages of the parasite and prevent disease symptoms or
to treat the disease by killing blood stages of the
parasite.
In Additional file 18 we ranked predicted drug target
reactions that do not correspond to our gold standard
set, but are associated with genes, according to a score
that represents the sum of weighting factors associated
with the following criteria: weighting factor 2 if corre-
sponding genes are not homologous to human genes,
weighting factor 1 if the enzymatic function is targeted
in any organism (i. e., EC number is listed in the Super-
Target database) and weighting factor 1 if the reaction
is active during all parasitic life cycle stages, which
makes respective drugs applicable for prophylaxis as
well as disease treatment. The 30 top ranking targets are
listed in Table 4. Strikingly, among the eight top ranking
enzymes/transporters four enzymes and one transporter
are assigned to the apicoplast, which harbors prokaryo-
tic biochemical pathways and was therefore proposed as
an interesting drug target [82,83]. Three of these top
ranking enzymes are involved in the biosynthesis of iso-
pentenyl diphosphate (IPP). Since two enzymes of the
IPP biosynthesis pathway (1-deoxy-D-xylulose-5-phos-
phate reductoisomerase, 2-C-methyl-D-erythritol-2,4-
cyclodiphosphate-synthase) have already been suggested
as potential targets for antimalarial therapy [84-86], it is
likely that other enzymes of this linear pathway have
also this potency. P. falciparum possesses a pathway to
synthesize pyrimidine nucleotides de novo of which mul-
tiple reactions are predicted to be essential. Some of the
corresponding enzymes (carbonic anhydrase, carbamoyl-
phosphate synthase, dihydroorotase, dihydroorotate oxi-
dase, orotidine-5’-phosphate decarboxylase) have already
been confirmed by experiments to have negative effects
on parasite growth upon inhibition [87-98]. These
experiments suggest that the parasite is not able to sal-
vage pyrimidine nucleotides and thus other enzymes
that catalyze intermediate biosynthesis reaction steps
might be likewise essential as proposed by our predic-
tions. The heme biosynthesis pathway has previously
been proposed as a target for antimalarial drugs
[99-101], as heme is needed as a prosthetic group in
proteins such as cytochromes. Heme, which is freed in
large amounts during hemoglobin digestion, is
Table 3 Gold standard set of essential enzymes (Continued)
4.1.2.13 Fructose-bisphosphate aldolase Yes No Presumable main antimalarial effect is impaired host cell
invasion
[187,188]
4.2.1.1 carbonic anhydrase Yes Yes [87]
4.2.1.24 Delta-aminolevulinic acid
dehydratase
No Yes [100]
4.2.1.58-
61
3-hydroxyacyl-ACP dehydratase Yes Yes [189]
4.2.3.5 Chorismate synthase Yes No Precursor import (4-aminobenzoate, folate) [92]
4.4.1.5 Lactoylglutathione lyase Yes Yes [190]
4.6.1.12 2-C-methyl-D-erythritol-2,4-
Cyclodiphosphate-synthase
No Yes [86]
5.99.1.2 topoisomerase I Yes Yes [191]
5.99.1.3 topoisomerase II Yes Yes [192-194]
6.1.1.3 Threonine-tRNA ligase Yes Yes [195]
6.1.1.7 Alanine-tRNA ligase Yes Yes [196]
6.3.2.2 Gamma-glutamylcysteine synthetase Yes Yes [144,197,198]
6.3.4.4 Adenylosuccinate synthetase Yes Yes [199]
6.3.5.2 GMP synthetase No No Necessary to block all reactions catalyzed by the enzyme;
precursor import(guanine/guanosine)
[200]
6.3.5.5 Carbamoyl-phosphate synthase
(glutamine-hydrolysing)
No Yes [88]
6.3.5.8 amino-deoxychorismate synthase No No Precursor import (4-aminobenzoate, folate) [128]
6.4.1.2 Acetyl-CoA carboxylase Yes Yes [156]
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food vacuole [99,102], making de novo synthesis essen-
tial. This is in accordance with our predictions that clas-
sified several enzymes involved in heme biosynthesis to
be indispensable. Another pathway that contains reac-
tions predicted to be essential is that of Coenzyme A
biosynthesis. It has been demonstrated that the parasite
relies on the uptake of pantothenate, a precursor of
CoA, and that it is sensitive to pantothenate analogs
[103]. Therefore, inhibition of downstream enzymes
within this linear pathway might hamper parasite
growth as well. Multiple top ranking enzymes are
involved in the process of protein biosynthesis (tRNA
ligases, deoxyhypusine synthase). The eukaryotic initia-
tion factor, whose activation involves deoxyhypusine
synthase, has already been suggested to be the target of
a drug with antimalarial effect [104]. Little is known
about the translational machinery of P. falciparum
despite the obvious global effect upon its inhibition.
Therefore, an EU funded consortium called MEPHITIS
has started very recently to explore the protein synthesis
machinery in Plasmodium with the goal to design drugs
against malaria. Adenylate cyclase obtained among
others the highest score by our scoring function. Experi-
mental findings by Ono et al. [105] indicate that knock-
outs of adenylate cyclase result in a decreased level of
cAMP, leading to reduced apical regulated exocytosis
and thus impaired infection of host cells. The essential-
ity of this enzyme is therefore rather related to signaling
than to metabolism, but nevertheless represents an
effective target. These evidences for the plausibility of
our results together with the proven high specificity and
accuracy rates for known targets indicate that the pre-
dicted set of essential reactions presents a promising
starting point for further experimental investigations.
Discussion
This study has been conducted to explore the capabil-
ities of computational methods to predict metabolic
activities during different life cycle stages of the malaria
pathogen P. falciparum, and furthermore to identify
drug targets, given currently available large scale data.
For this purpose, a metabolic network was compiled
from available resources, which is able to fulfill meta-
bolic functions known from the literature to occur in P.
falciparum. A common approach to get an insight into
the metabolism of an organism is to analyze gene
expression data, since this kind of data can be obtained
easier than metabolomics data. However, metabolic
fluxes do not always correlate well with the transcrip-
tome of a cell [52-55], so that from expression profiles
alone no information about flux strength and direction
can be gained. Especially in cases where no expression
data is available for the pathway of interest, e. g. if no
genes are assigned to reactions yet, other methods are
needed. The presented flux balance approach facilitates
the prediction of stage-specific metabolic flux distribu-
tions in accordance with observed gene expression,
without requiring detailed kinetic information. In con-
trast to the original method proposed by Shlomi et al.,
our approach ensures the production of metabolites
assumed to be important for parasite development
(phospholipids, amino acids, nucleotides, etc.), yielding
presumably more realistic flux predictions. In addition,
we simulated host cell conditions for the blood stage
parasite by combining the metabolic networks of para-
site and erythrocyte and constraining nutrient supply.
Predicted nutrient uptake and product secretion were
shown to largely agree with experimental findings sug-
gesting that our model of the parasitic metabolism is
realistic especially when integrated into its actual
environment.
Experimental validation of drug targets by gene
knockout techniques is a time consuming issue. Flux
b a l a n c ea n a l y s i sp r o v i d e saf a s tm e a n st or e d u c et h e
search space. Reactions essential for parasite develop-
ment are proposed based on their involvement in synth-
esis processes of indispensable metabolites. Our drug
target predictions were evaluated on the basis of a set of
known essential enzymes, revealing that the method is
Figure 3 Evaluation of predicted drug targets. We conducted
FBA based knock-out simulations to uncover reactions within the
metabolic network of the parasite that are essential for the
production of metabolites assumed to be important for parasite
development (see Additional file9). The predicted set of
indispensable reactions, which presumably represent good drug
targets, was evaluated on the basis of a gold standard set that
contains 57 experimentally verified essential enzymes. We
determined true positives (TP), false positives (FP), false negatives
(FN), and true negatives (TN) and calculated based on these
numbers sensitivity, specificity, accuracy and precision of our
method as well as the corresponding enrichment factor (red
numbers). To compare our method to a previously proposed
method for drug target detection, the choke-point analysis, we
additionally identified all choke-points within the parasite’s
metabolic network and calculated the same statistics (green
numbers).
Huthmacher et al. BMC Systems Biology 2010, 4:120
http://www.biomedcentral.com/1752-0509/4/120
Page 15 of 27able to enrich true targets in the set of predicted targets.
The benefits of our FBA approach are good perfor-
mance (compared to the previously proposed choke-
point analysis [23,24]) and short computation times.
The latter plays a role especially when the metabolic
network of interest is large and beyond the capabilities
of topology based methods such as Minimal Cut Sets
[106]. We used additional information such as homology
to host enzymes and reported negative effects on cell
development in other organisms to rank proposed tar-
gets. As has been shown for fatty acid synthase [51],
which is only essential during late liver stage, the impor-
tance of enzymes might vary during different life cycle
stages. Therefore, predictions on metabolic fluxes during
different time points of parasite development can help
to identify reactions that are always active and those
that only occur during certain stages, thereby aiding the
drug target detection process.
In general, the quality of results derived from compu-
tational methods depends heavily on the information
used to attain them. For example, about 50% of the pre-
dicted genes in P. falciparum are not annotated yet, sug-
gesting that our compiled metabolic network is not
complete. Furthermore, as pointed out by Ginsburg
[107], most of the dababases (BioCyc, KEGG, Reactome)
infer metabolic pathways computationally, which results
in predictions where actually only one or two enzymes
of the pathway are associated with genomic sequences
and therefore very likely do not occur in the parasite.
To cope with this problem, we removed those pathways
that are suggested by [107] to be not present in P. falci-
parum, and in addition, penalized reactions without
associated genes in our flux balance calculations. On the
one hand, confidence in our drug target predictions
increases when such pathways are removed. On the
other hand, we might miss interesting targets that are
products of yet unannotated genes. For the drug devel-
opment process, knowledge about the target protein is
desired, making predicted target reactions without
assigned genes less attractive for further investigation
and thus justifies the removal of uncertain pathways.
In addition, one has to keep in mind that the gene
expression data sets applied to infer metabolism during
the individual life cycle stages are of varying quality.
While the blood stage is covered on a close-meshed
time scale, the liver stage and especially the mosquito
stage are less well analyzed. There’sa l s ot h ef a c tt h a t
the latter stages have partially only been examined in
the rodent malaria pathogen which might be different in
certain aspects to that of the human malaria pathogen
P. falciparum. Moreover, the Sacci data set is less
expressive than other corresponding data sets, as it is
based on a cDNA library rather than microarray analysis
and thus captures only part of the true liver stage
transcriptome. On top of this, the overall knowledge
about the liver and the mosquito stages is still limited
compared to the blood stage. As a consequence less
information can be included into the models for these
stages, making derived predictions less reliable than
those for the blood stage.
The accuracy of our predictions is further influenced
by the applied criteria that define gene expression as
well as posttranscriptional regulation which might lead
to discrepancies in transcriptomic and proteomic data.
Proteomics and metabolomics data are desirable, as
enzyme and metabolite levels give a better picture on
the metabolic status of a cell than mRNA levels. Such
data is currently not available for as many time points
and enzymes/metabolites as it is the case for transcrip-
tomic data. Metabolomics s t u d i e sh a v eo n l yv e r y
recently become available for P. falciparum, which mea-
sured concentrations for a few metabolites during the
blood stage [43,108]. When metabolite concentrations
will be available on a larger scale, our method can be
extended to incorporate such data. For example, for
each detected metabolite one could force at least one
reaction producing the metabolite to be active, in order
to ensure production of this metabolite. However, meta-
bolite measurements during a single time point do not
elucidate whether a metabolite is mainly produced or
consumed during the time point of interest and thus
such a model extension could be inappropriate. Such
information can only be deduced from measurements of
two consecutive life cycle time points. Corresponding
fluxes could then be fixed in simulations to the differ-
ence between the metabolite levels measured during
these time points divided by the time difference. Mea-
sured metabolite concentrations could also help to
attain flux distributions that are consistent with thermo-
dynamics as has been shown in [109]. Predictions could
be further improved if more information were available
on reaction irreversibilities, transporter capacities, feed-
back regulations, and nutritional conditions within the
different hosts. Last but not least, an accurate definition
of target metabolites that are produced during each life
cycle stage is needed to obtain good flux predictions for
individual stages. Until such data is available, the
approach presented here facilitates the generation of
working hypotheses that can then be experimentally
validated, thereby enhancing the knowledge on the
malaria pathogen P. falciparum.
Conclusions
Malaria is still a worldwide health problem and initia-
t i v e st of i g h tt h i sd i s e a s eh a v et of a c et h ei n c r e a s i n g
spread of resistances to currently available drugs. In this
paper, we presented the first compartmentalized meta-
bolic network model of the malaria pathogen
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tational methods contribute to malaria research. We
introduced a flux balance approach to predict life cycle
stage specific metabolism on the basis of gene expres-
sion data. Good accordance between predictions and
experimental findings was observed for metabolite
exchanges between the parasite and its host the human
erythrocyte. In order to obtain reliable predictions addi-
tional information about the parasite’s environment was
required, which was implemented by combining the
parasite’s metabolic network with one of its hosts (ery-
throcyte) as well as constraints reflecting knowledge
about the blood stage. The metabolic network of the
hepatocyte, which is currently reconstructed within our
group, will soon be available and allow improved predic-
tions in a similar way for liver stage metabolism about
which only little is known yet. We additionally con-
ducted knock-out simulations, which revealed a set of
indispensable reactions, representing putative drug tar-
gets. Evaluation of this set on the basis of experimentally
validated essential enzymes confirmed the power of our
predictions. Thus, computational methods as presented
here have the ability to reduce the search space for
novel drug targets in the metabolism of the P.
falciparum.
Methods
Metabolic network compilation
To obtain a network that describes the parasitic metabo-
lism as completely as possible, data from multiple online
resources have been integrated in the compilation pro-
cess. Biochemical reactions were gathered from the
Table 4 Top ranking predicted essential reactions
Enzyme name Compartment Pathway EC Super-
Target
Score
adenylate cyclase apicoplast Purine metabolism 4.6.1.1 x 4
fumarase cytosol Citrate cycle 4.2.1.2 x 4
2-C-methyl-D-erythritol 4-phosphate
cytidylyltransferase
apicoplast Biosynthesis of isopentenyl
diphosphate
2.7.7.60 x 4
4-hydroxy-3-methylbut-2-enoyl-
diphosphate synthase
apicoplast Biosynthesis of isopentenyl
diphosphate
1.17.4.3 3
CDP-ME kinase apicoplast Biosynthesis of isopentenyl
diphosphate
2.7.1.148 3
pantetheine-phosphate
adenylyltransferase
cytosol CoA biosynthesis 2.7.7.3 3
pyridoxal 5-phosphate synthase cytosol Vitamin B6 metabolism 3
amino acid transporter Cytosol ↔ apicoplast Transport 3
geranyl-diphosphate synthase cytosol Terpenoid biosynthesis 2.5.1.1 x 2
farnesyl-diphosphate synthase cytosol Terpenoid biosynthesis 2.5.1.10 x 2
2-Octaprenylphenol hydroxylase mitochondrion Ubiquinone biosynthesis 1.14.13.- x 2
ubiquinone biosynthesis
methyltransferase
mitochondrion Ubiquinone biosynthesis 2.1.1.- x 2
uroporphyrinogen decarboxylase apicoplast Porphyrin metabolism 4.1.1.37 x 2
coproporphyrinogen oxidase apicoplast Porphyrin metabolism 1.3.3.3 x 2
UMP-CMP kinase apicoplast Pyrimidine metabolism 2.7.4.14 x 2
aspartate carbamoyltransferase cytosol Pyrimidine metabolism 2.1.3.2 x 2
orotate phosphoribosyltransferase cytosol Pyrimidine metabolism 2.4.2.10 x 2
cysteine desulfurase apicoplast/
mitochondrion
Fe-S-protein biogenesis 2.8.1.7 x 2
tRNA ligase (Ile, Lys, Met, Trp, Tyr) cytosol/apicoplast/
mitochondrion
Aminoacyl-tRNA biosynthesis 6.1.1.1/6.1.1.2/6.1.1.5/
6.1.1.6/6.1.1.10
x2
glutathione synthase cytosol Glutathione metabolism 6.3.2.3 x 2
riboflavin kinase cytosol Riboflavin metabolism 2.7.1.26 x 2
glucosamine 6-phosphate synthase apicoplast Aminosugars metabolism 2.6.1.16 x 2
mannose-6-phosphate isomerase cytosol Fructose and mannose
metabolism
5.3.1.8 x 2
cytochrome-c oxidase mitochondrion Oxidative phosphorylation 1.9.3.1 x 2
choline-phosphate cytidylyltransferase cytosol Glycerophospholipid
metabolism
2.7.7.15 x 2
deoxyhypusine synthase cytosol Activation of eiF5A 2.5.1.46 x 2
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(http://sites.huji.ac.il/malaria/, November 2007), the
KEGG database (http://www.genome.jp/kegg/, February
2009), the BioCyc database (http://biocyc.org/, release of
August 6th 2007 for P. falciparum 3D7), the Reactome
database (http://www.reactome.org/, November 2007),
and the BRENDA database (http://www.brenda-
enzymes.org/, January 2007). KEGG reactions were con-
sidered as present in P. falciparum,i fg e n e sw e r e
a s s i g n e dv i at h eK E G GO r t h o l o g y( K O ) ,ac l a s s i f i c a t i o n
of orthologous and paralogous groups of genes based on
high sequence similarities to genes of known function.
Since each resource uses individual identifiers for reac-
tions and metabolites, it was necessary to map the reac-
tions onto each other. The KEGG identifiers were
chosen as an overall means of identification. P. falci-
parum reactions suggested by BioCyc and Reactome
were mapped to KEGG reactions via annotated genes or
EC numbers. In case that way the corresponding KEGG
reaction was not found, involved metabolites were
mapped to KEGG metabolites either with the help of
annotated ChEBI or PubChem identifiers or, if such
cross-references were not available, PubChem and
ChEBI were queried for matching synonyms. The KEGG
metabolite identifiers were then assembled to find the
corresponding KEGG reaction. Hagai Gins-burg kindly
provided a list of genes and EC numbers corresponding
to metabolic pathways known to occur in P. falciparum.
All KEGG reactions associated with these EC numbers
were checked for their presence in any of the pathways
depicted at the MPMP website and, where appropriate,
added to the parasite’s metabolic network. Similarly, all
KEGG reactions associated with EC numbers that are
annotated as present in P. falciparum by the BRENDA
database were included in the network. For several reac-
tions listed by the different online resources no match-
ing KEGG reaction could be found. In such cases, the
reaction equation translated to respective KEGG meta-
bolites was assigned with a new unique identifier start-
ing with the letter ‘Q’ followed by five digits in
accordance to the KEGG identifiers. Since BioCyc reac-
tions are mostly computationally inferred, we removed
reactions that are associated to pathways that are
assumed to be not present in P. falciparum [107], except
for the chorismate biosynthesis pathway.
Each reaction of the resulting metabolic network was
assigned to one of the following compartments: cytosol,
nucleus, mitochondrion, apicoplast, endoplasmic reticu-
lum, or food vacuole. The default compartment for all
reactions is the cytosol. This assignment was overruled
if the corresponding gene is annotated with Gene
Ontology terms [110] within the PlasmoDB database
[111] that refer to another compartment. Compartment
reassignment was done as well for reactions either
assigned by the MPMP website to a different compart-
ment or when corresponding genes contain signal
sequences for the apicoplast or mitochondrion. Informa-
tion on transporters transferring metabolites between
the different compartments as well as between the host
and the parasite, were mostly obtained from the MPMP
website, and in addition, from the Transport Classifica-
tion database http://www.tcdb.org/, BioCyc, and Reac-
tome database. The metabolic networks of P. falciparum
and the human erythrocyte are both available as SBML
files (Additional files 1 and 2).
Consistency checks
In a first step highly specific metabolites such as beta-D-
Glucose were replaced by more general metabolites (D-
Glucose), using a manually compiled list of substitu-
tions. Moreover, if the same metabolite occurs with dif-
ferent IDs in reactions, one was chosen to replace
alternative IDs. Reactions containing generic terms like
‘acceptor’ or ‘fatty acid’ were either removed, replaced
by more specific reactions or, if the generic metabolite
matched multiple specific metabolites, a pseudo-reaction
was added converting the metabolite in more specific
ones (e. g. fatty acid ® hexadecanoate + (9Z)-Hexadece-
noic-acid + octadecanoic-acid + (9Z)-Octadecenoic-acid
+ (9Z,12Z)-Octadecadienoic-acid). Furthermore, generic
reactions (A + n B ® n C + D) were removed. Finally,
reaction duplets were deleted that were already present
in the original data or were generated by the consistency
procedure.
Flux balance analysis
Flux balance analysis (FBA) is a commonly used
method to investigate the metabolic capabilities of cel-
lular systems, since it allows to estimate unknown
fluxes in metabolic networks with respect to cellular
constraints [10,19,112-115]. Among others, FBA has
been used for metabolic engineering studies [116,117],
drug target prediction [118-120] as well as growth pre-
diction on different media [121,122]. In contrast to
kinetic modeling no detailed rate equations are
required, predestining the method for large metabolic
networks, which lack full kinetic characterization of all
enzymes. Prerequisite for application of this method is
the stoichiometric matrix S, which describes the num-
ber of metabolite molecules consumed and produced
by each reaction of the metabolic network, as well as
knowledge about the cellular objective. The basis of
FBA is the flux conservation principle, which assumes
t h es y s t e mt ob ea tq u a s is t e a d ys t a t ew i t hm e t a b o l i t e
concentrations [X] and reaction fluxes v being con-
stant, since bio-chemical reactions are typically much
faster than changes in the phenotype of a cell during
growth or differentiation:
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The solution space of the resultant linear equation
system is a high dimensional flux cone, containing all
flux configurations that are feasible at steady state. Con-
straints derived from thermodynamics and cellular
environment conditions further restrict the solution
space. Organisms are thought to be optimized in the
course of evolution. Therefore, a biologically meaningful
objective function, which is a linear function of fluxes, is
applied to the set of possible solutions to identify a flux
distribution that is optimal with respect to the cellular
objective. Maximization of biomass is one such target
function that is assumed to be suitable especially for
microorganisms [123]. For eukaryotic cells such as hepa-
tocytes, for which reproduction is not the primary goal,
cellular maintenance at minimal efforts has been pro-
posed as an alternative objective function [124]. Alto-
gether this yields the following formalism:
min/ max ( )
:(
v
T cv
Sv
objective function
s. t. steady state ass = 0u umption
constraints
)
() min, max, vv v ii i <<
where S is the stoichiometric matrix of the cellular
system, v a r ei n t e r n a lf l u x e sa sw e l la se x c h a n g ef l u x e s ,
and vmin and vmax a r et h el o w e ra n du p p e rb o u n d so n
fluxes.
Evaluating the expression status of genes
The expression status was determined for each gene of
every expression sample. For the Le Roch data set the
same parameter cutoffs were applied as mentioned in [6]
(thermocycling treatments data): expression level E >1 0
and likelihood of gene absence calculated by the match-
only integral distribution algorithm logP < -0.5. Genes
covered by the Bozdech and Tarun data sets were consid-
ered to be expressed if the corresponding signal-to-noise
ratio (s2n =( mean(Foreground signal)-mean
(Background signal))/std(Background signal),
with Foreground signal being the signal resulting
from specific hybridization and Background signal
being the noise caused by non-specific binding), is
greater or equal to a threshold. Signal-to-noise ratios
were extracted from the raw data, averaged over all repli-
cates and normalized using quantile normalization [125].
Applying a too low or too high threshold results in
almost all genes being expressed or silenced, respectively.
Therefore, the threshold t was chosen for the Bozdech
data set in such a way that the average Euclidean distance
between the binary expression values (expr (g | t)=0:
gene g is silent given threshold t, expr (g | t)=1: gene g is
expressed given threshold t) is maximal for non-consecu-
tive pairs of samples of the same data set and minimal
for consecutive pairs:
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where N is the number of gene expression samples, M
is the number of genes and ik is the k
th gene in sample i.
A threshold of 17 turned out to be optimal. This
approach could not be applied to the Tarun set, since the
time span between extractions of samples is much larger.
Instead, the signal-to-noise ratio threshold was set to 25
which yielded largest similarity between Tarun samples
and corresponding Le Roch samples. As the Sacci data
set is a cDNA library that captures mRNA present at a
certain time point, all genes of the library were accounted
as expressed. For the Daily samples a gene expression sig-
nal cutoff of 139 yielded largest similarity between sam-
ples of cluster 2 (active growth) and ring stage expression
samples of the Le Roch set and was therefore used to
determine expression in Daily samples.
Calculating flux distributions consistent with gene
expression data
Flux distributions were predicted for the different life
cycle stages of the malaria pathogen with an extended
version of the method proposed by Shlomi et al. [25].
This method is a flux balance approach with additional
binary variables for reactions with associated gene
expression data. Constraints force reactions to have a
non-zero (zero) flux value if the respective gene is
expressed (not expressed) and the corresponding binary
variable (y1p (forward direction), y1n (backward direc-
tion), y0 (no flux)) is set to 1. The sum of these binary
variables composes the objective function that is sought
to be maximized to obtain flux distributions that are
consistent with corresponding expression profiles. How-
ever, the Shlomi method has several limitations: synth-
esis of metabolites needed for growth is not guaranteed,
reactions of low confidence are treated the same as
those with annotated genes, in order to maximize the
objective function all reactions catalyzed by the same
gene product are sought to be active simultaneously in
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set on available nutrients. To cope with these issues we
extended the method as follows. (a) Additional con-
straints force the network to produce a set of target
metabolites that are assumed to be essential during the
life cycle stage of interest (see Additional file 9). (b) For
all reactions that have no associated gene, boolean vari-
ables (y2,i) and constraints were introduced that keep
these reactions inactive if the respective variable is set
to 1. (c) For each expressed gene a boolean variable (y3,
i) and constraints were added, making sure that at least
one of the reactions associated to an expressed gene has
to carry a non-zero flux in case the respective variable is
set to 1. Replacing variables y1p and y1n in the objective
function with this variable type avoids that all reactions
catalyzed by the same expressed enzyme are sought to
be active at the same time to further optimize the objec-
tive function value. (d) With respect to the restrained
access of the parasite to nutrients of the host the net-
work is forced to fulfill its tasks with a minimum
amount of externally supplied metabolites by subtracting
the absolute flux valuest h r o u g ht h ep a r a s i t e ’sp l a s m a
membrane transporters from the objective function
value. (e) To simulate the parasites environment the
uptake of certain metabolites was constrained in accor-
dance with knowledge about the blood stage. The corre-
sponding mixed integer linear program reads as follows:
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Within the solution space, which is defined by equations
and inequalities (2)-(14), a flux distribution is sought that
maximizes the objective function described by (1). a
denotes the reward for setting the fluxes of reactions to
zero that correspond to unexpressed genes (RNE), b repre-
sents the reward for assigning a zero flux to such reactions
that are not associated with any gene (RNG), g denotes the
reward for having a non-zero flux through any reaction
assigned to an expressed gene (GE), while δ is the penalty
for forward fluxes v
+ through parasitic plasma membrane
transporters (T) importing external metabolites. In our
calculations the variables were set as follows: a =2 ,b =
0.1, g = 1, and δ = 0.5. Inequalities (5)-(7) are the same as
in [25] and (8) is analogous to (7) to obtain a zero flux
through reactions without associated gene. The subse-
quent inequalities (9)-(11) ensure that if a binary variable
of type y3 is set to 1, at least one of the corresponding vari-
ables of type y1 have to equal 1 as well. Matching variables
y1 and y3 are identified via function r(i) that maps a gene
onto a set of reactions that are catalyzed by the gene pro-
duct. Biomass production is ensured by (4), which requires
ef l u x e so fa tl e a s to n em o l e c u l eo ft h er e s p e c t i v et a r g e t
metabolites through system boundaries.
Detection of essential reactions
FBA methods can be used to determine reactions of a
metabolic network that are essential for the synthesis of
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simulating the effects of knocked-out genes
[118-120,126,127]. The linear program underlying the
knock-out simulations of this study consists of equations
derived from the steady state assumption as well as
thermodynamic constraints and constraints demanding
the production of metabolites assumed to be essential
during any time point of parasite development (equation
(2) and inequalities (3) and (4) of previous section). In
addition, fluxes through a reaction of interest are fixed
to zero, mimicking the knock-out of the corresponding
gene. For each reaction of the metabolic network of P.
falciparum such a linear program was formulated. In
case the solution space of the problem was empty, the
knocked-out reaction was considered to be indispensa-
ble and thus a putative drug target, since no path exists
converting external nutrients into all target metabolites,
which presumably results in impaired parsite develop-
ment. In contrast to the previously conducted flux bal-
ance analysis no gene expression is considered for the
identification of essential reactions.
Additional material
Additional file 1: Assembled metabolic network of P. falciparum in
SBML format.
Additional file 2: Assembled metabolic network of the human
erythrocyte in SBML format.
Additional file 3: Gene expression samples. In order to calculate a
stage-specific flux distributions our flux balance approach requires a
gene expression profile of the stage of interest. We obtained gene
expression samples from different publications, including Bozdech et al.,
Le Roch et al., Sacci et al., and Tarun et al.
Additional file 4: Normalized Hamming distance matrix for gene
expression samples. In order to compare the gene expression profiles
of the different time points normalized Hamming distances (see text for
formula) have been calculated as described in the text for each pair of
gene expression samples. The darker the color of a matrix entry, the
lower is the corresponding Hamming distance. Sample labels are
composed of the sample abbreviation and the number of expressed
genes.
Additional file 5: Bozdech gene expression samples mapped onto
metabolic pathways. Mapping gene expression data onto metabolic
networks may uncover active pathways for each stage and metabolic
differences between the individual life cycle stages. For this purpose, we
calculated the ratio of expressed genes per KEGG pathway (# expressed
genes/# genes with available expression data for pathway) for each
Bozdech gene expression sample. The darker the color of a matrix entry,
the lower is the ratio. Clusters of pathways with similar patterns of
expressed genes during the individual life cycle time points were
calculated with the built-in function hclust (’average’ method) of the
statistics software R (colored bars).
Additional file 6: Le Roch gene expression samples mapped onto
metabolic pathways. See caption of Additional file 5.
Additional file 7: Tarun gene expression samples mapped onto
metabolic pathways. See caption of Additional file 5.
Additional file 8: Daily gene expression samples mapped onto
metabolic pathways. See caption of Additional file 5.
Additional file 9: Metabolites essential for parasite development.
Metabolites listed in this table are assumed to be essential during those
developmental stages of the parasite that are specified in the third
column. Some entries represent pseudo-metabolites that do not
correspond to actual metabolites. These have been added as products in
the equations of certain important reactions such as glutathione
reductase. Requiring the production of these pseudo-metabolite ensures
that the respective reaction is active.
Additional file 10: Normalized Hamming distance matrix for
calculated flux distributions. Flux distributions have been predicted
with our flux balance approach (see Figure 1) for each time point of the
parasite’s life cycle for which a gene expression profile exists. Simulations
were conducted considering only the metabolic network of the parasite
without any further constraints reflecting the parasite’s environment and
without considering the expression status of genes during preceding
time points. In order to compare the individual flux distributions
normalized Hamming distances (see text for formula) have been
determined for all pairs of flux distributions. The darker the color of a
matrix entry, the lower is the corresponding Hamming distance.
Additional file 11: Predicted host parasite metabolite exchanges.
Flux distributions have been predicted with our flux balance approach
(see Figure 1) for each time point of the parasite’s life cycle for which a
gene expression profile exists. Simulations were conducted considering
only the metabolic network of the parasite without any further
constraints reflecting the parasite’s environment and without considering
the expression status of genes during preceding time points. Resulting
metabolite exchanges between host and parasite are depicted in this
figure. Red matrix entries represent metabolites that are predicted to be
imported into the parasite while green matrix entries represent
metabolites secreted into the host compartment.
Additional file 12: Normalized Hamming distance matrix for
calculated flux distributions using improved approach. Flux
distributions have been predicted with our improved flux balance
approach (see Figure 1) for each time point of the intraerythrocytic
developmental cycle for which a gene expression profile exists.
Simulations were conducted on the basis of the combined metabolic
network of parasite and host and additional constraints reflecting
knowledge about the blood stage. Furthermore, the expression status of
genes during preceding time points was considered for the flux
calculations. In order to compare the individual flux distributions
normalized Hamming distances (see text for formula) have been
determined for all pairs of flux distributions. The darker the color of a
matrix entry, the lower is the corresponding Hamming distance.
Additional file 13: Reaction distribution among stage-specific fluxes.
Flux distributions have been predicted with our improved flux balance
approach (see Figure 1) for each time point of the intraerythrocytic
developmental cycle for which a gene expression profile exists.
Simulations were conducted on the basis of the combined metabolic
network of parasite and host and additional constraints reflecting
knowledge about the blood stage. Furthermore, the expression status of
genes during preceding time points was considered for the flux
calculations. Subsequently, it was counted in how many of these stage-
specific flux distributions a particular reaction was carrying a non-zero
flux. The resulting histogram is shown here. The x-axis gives the number
of flux distributions within which a reaction carries a non-zero flux and
the y-axis indicates the frequency. In other words, the left most bar of
the histogram represents the number of reactions that exclusively occur
in a single flux distribution and are therefore very stage-specific, while
the right most bar represents the number of reactions that are present
in all (96) flux distributions related to the blood stage.
Additional file 14: Predicted metabolic fluxes consistent with
Bozdech gene expression data mapped onto metabolic pathways.
Flux distributions have been predicted with our improved flux balance
approach (see Figure 1) for each time point of the intraerythrocytic
developmental cycle for which a gene expression profile exists.
Simulations were conducted on the basis of the combined metabolic
network of parasite and host and additional constraints reflecting
knowledge about the blood stage. Furthermore, the expression status of
genes during preceding time points was considered for the flux
calculations. In order to explore the predicted flux distributions on the
level of metabolic pathways, we mapped the flux profiles onto KEGG
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active or not and wether there are changes during the IDC. The darker
the color of a matrix entry the fewer reactions of the corresponding
pathway are active.
Additional file 15: Predicted metabolic fluxes consistent with Le
Roch gene expression data mapped onto metabolic pathways.
Same as Additional file 14 but fluxes were calculated using Le Roch gene
expression data.
Additional file 16: Predicted metabolic fluxes consistent with Daily
gene expression data mapped onto metabolic pathways. Same as
Additional file 14 but fluxes were calculated using Daily gene expression
data.
Additional file 17: Overview of pathway specific consensus
reactions for different time points of intraerythrocytic cycle. Flux
distributions have been predicted with our improved flux balance
approach (see Figure 1) for each time point of the intraerythrocytic
developmental cycle for which a gene expression profile exists.
Simulations were conducted on the basis of the combined metabolic
network of parasite and host and additional constraints reflecting
knowledge about the blood stage. Furthermore, the expression status of
genes during preceding time points was considered for the flux
calculations. Consensus reactions, which are reactions that are predicted
to be active for all gene expression samples covering the same stage,
were determined. These reactions are more likely to actually occur
during a certain stage, since they are derived from different data
samples. In order to identify consensus reactions we grouped all
calculated flux profiles corresponding to the blood stage into seven sets
(eRing, lRing, eTropho, lTropho, eSchiz, lSchiz, Mero; see Additional file 3)
with respect to represented stages and determined those reactions that
carry a non-zero flux in all flux profiles of the same set. For each blood
stage and each metabolic pathway the fraction of consensus reactions
per total number of pathway reactions was computed to uncover the
distribution of consensus reactions among pathways. To get an
impression of how many consensus reactions are shared between the
different stages, this fraction was also computed for those consensus
reactions that two sets have in common. The darker the color of a
matrix entry the lower is the percentage of consensus reactions.
Additional file 18: Ranked predicted essential reactions. Knock-outs
were simulated with a simple FBA approach neglecting gene expression
information. No assumptions were made about the cellular environment
and nutrient uptake was not restricted, since such information is not
available for all stages. Successively reactions were constrained to carry
no flux, while the network was forced to produce all metabolites that are
assumed to be essential during any developmental stage (all metabolites
listed in Additional file 9). If no solution could be found to this problem
the reaction was assumed to be essential. The resulting set of
indispensable reactions, which are assigned to genes and not covered by
our gold standard set of experimentally validated essential enzymes, is
listed here. Reactions are ranked according to a score that is derived as
follows: two points if corresponding genes are not homologous to
human genes, an additional point if the reaction is targeted in any other
organism (according to the SuperTarget database), and another
additional point if the reaction is active during all parasitic life cycle
stages, which makes respective drugs applicable for prophylaxis as well
as disease treatment.
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